GSTM1 and chronic kidney disease: Recently, the results of post hoc analysis of two double-blind, randomized, phase 3 study in DD-CKD or in NDD-CKD patients assessed the impact of factors associated with ESA hyporesponsiveness on roxadustat and darbepoetin alfa doses indicated that roxadustat doses required to maintain target Hb appear to be less affected by factors that underlie ESA hyporesponsiveness, relative to ESA (Akizawa et al., 2021b; Akizawa et al., 2021c).